Consumer products group Reckitt Benckiser posted a trading update for its first quarter on Friday, reporting it was in line with expectations with continued strong performance in the health division led by Mucinex and Durex.
The FTSE 100 firm said that growth was offset by headwind in Scholl / Amopé, which also impacted Europe-North America performance.
Growth rates were set to improve through the year, and RB said it was on track for its full year net revenue target of 3% like-for-like.
Disclaimer: The opinions expressed by our writers are their own and do not represent the views of Precise Investors. The information provided on Precise Investors is intended for informational purposes only. Precise Investors is not liable for any financial losses incurred. Conduct your own research by contacting financial experts before making any investment decisions.
